The loss of Enanta Pharmaceuticals under GAAP for the 3 months of fiscal year 2022 was $30.115 million, increasing 3.6 times compared to $8.328 million in the previous year. Revenue decreased 12.9% to $27.648 million from $31.743 million a year earlier.
The loss of Enanta Pharmaceuticals under GAAP for the 3 months of fiscal year 2022 was $30.115 million, increasing 3.6 times compared to $8.328 million in the previous year. Revenue decreased 12.9% to $27.648 million from $31.743 million a year earlier. 
enanta.com
English (US) 